Monoacylglycerol O-acyltransferase 2 (MOGAT2) plays a significant role in influencing colorectal cancer (CRC) progression by regulating lipid metabolism through ACSM1 (Acyl-CoA synthetase medium-chain family member 1). In a study investigating MOGAT2’s role, researchers found that its expression directly impacts tumor behavior.
Monoacylglycerol O-acyltransferase 2 (MOGAT2) plays a significant role in influencing colorectal cancer (CRC) progression by regulating lipid metabolism through ACSM1 (Acyl-CoA synthetase medium-chain family member 1). In a study investigating MOGAT2’s role, researchers found that its expression directly impacts tumor behavior. When MOGAT2 was suppressed, CRC cells exhibited aggressive characteristics, including increased proliferation, invasion, and colony formation, along with reduced apoptosis (cell death). These changes suggest a more malignant cancer phenotype. On the other hand, overexpressing MOGAT2 reversed these effects, reducing tumor growth and invasion, promoting apoptosis, and inhibiting epithelial-mesenchymal transition (EMT), a process critical for cancer metastasis.
Mechanistically, MOGAT2 reprograms lipid metabolism in CRC cells. It reduces the accumulation of free fatty acids, regulates cholesterol transport, and suppresses the expression of lipid synthesis enzymes like GPAT2, GPAT3, and GAAT. This reprogramming helps restore metabolic balance in cancer cells, which is crucial for controlling their growth and spread.
Further analysis identified ACSM1 as a key downstream mediator of MOGAT2’s tumor-suppressive effects. ACSM1 contributes to the metabolic changes induced by MOGAT2. When ACSM1 was silenced, the beneficial effects of MOGAT2 overexpression were lost, and cancer cells regained aggressive traits, reduced apoptosis, and experienced metabolic dysregulation.
In summary, MOGAT2 acts as a tumor suppressor in CRC by modulating lipid metabolism through ACSM1. This pathway reduces tumor growth, promotes apoptosis, and inhibits invasion and EMT. Targeting the MOGAT2–ACSM1 axis may offer a promising therapeutic approach for managing CRC progression.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.